Translation of "substitution non réglementaire " (French → English) :

- stimulating further reduction of the regulatory and administrative burden by introducing elements that create synergies with, and allow for, closer operational links between EMAS and other EU legislation and instruments, thus reducing the administrative burden for EMAS registered organisations by way of regulatory flexibility, including both regulatory relief (substitution of legal requirements without changes in environmental legislation as such) or deregulation (changes in the legislation itself).

the revised process will be more transparent. The procedures for regulatory acceptance of new test methods will be published on the Commission's website once the current review is formalised. The current status of proposed alternative methods will be posted on a specific website to be set up by the JRC allowing interested parties to track progress; the information will be regularly updated. This will happen from the moment any proposed new alternative method undergoes a preliminary regulatory analysis. The website will also include an indication of decisions not to proceed with a particular test method and the reasons why such decisions ...[+++] are taken;

the revised process will be more transparent. The procedures for regulatory acceptance of new test methods will be published on the Commission's website once the current review is formalised. The current status of proposed alternative methods will be posted on a specific website to be set up by the JRC allowing interested parties to track progress; the information will be regularly updated. This will happen from the moment any proposed new alternative method undergoes a preliminary regulatory analysis. The website will also include an indication of decisions not to proceed with a particular test method and the reasons why such decisions ...[+++] are taken;

53. Account should also be taken of any existing legal, statutory or other regulatory requirements which could defeat a time-efficient entry into the relevant market and as a result discourage supply-side substitution.

The imposition by national regulatory authorities of mandated access that increases competition in the short-term should not reduce incentives for competitors to invest in alternative facilities that will secure more competition in the long-term.

Provided that the need to use embryos created by cell nuclear replacement is clearly demonstrated on a case-by-case basis with proper consent of the donors and under the regulatory control of the Human Fertilisation and Embryology Authority, the Expert Group is willing to support it and concludes that the potential benefit of discovering the mechanism for reprogramming adult cells and thereby providing compatible tissue for treatment justifies this transitional research involving the creation of embryos by cell nuclear replacement.